Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.
Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
Flash note
Healthcare |
Update
Carlos de Sousa
CEO
Gustav Gaudernack
CSO
Hans Vassgård Eid
CFO
Jens Bjørheim
CMO
Ton Berkien
CBO
Forecast net cash (NOKm)
346.1
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 9.6 | 5.1 | 30.8 |
Relative | 5.5 | (3.4) | 19.6 |
52 week high/low | NOK136.0/NOK59.9 |
Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential. Lead asset, UV1, activates the immune system to recognise cancer cells that express hTERT, which is present in c 85% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The broad R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total. Readouts are expected over 2023–25. The most near-term catalyst for the share price is topline readouts from the Phase II INITIUM study in malignant melanoma, expected in H124.
Y/E Dec | Revenue (NOKm) | EBITDA (NOKm) | PBT (NOKm) | EPS (fd) (öre) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2021A | 0.0 | (161.1) | (164.7) | (508.83) | N/A | N/A |
2022A | 0.0 | (181.0) | (167.8) | (489.06) | N/A | N/A |
2023E | 0.0 | (235.8) | (214.8) | (624.46) | N/A | N/A |
2024E | 0.0 | (274.0) | (277.9) | (807.84) | N/A | N/A |